- ■
BrainCheck raised $13 million to expand its enterprise cognitive care infrastructure and make cognitive health management more systematic and less fragmented
- ■
The company is integrating tighter clinical workflows, long term patient monitoring and population scale deployment across primary care and specialty settings
- ■
BrainCheck is investing in AI assisted clinical systems built for value based care models, where providers are rewarded for patient outcomes rather than service volume
- ■
Its core product, BrainCheck Assess™, is an FDA Class II cleared digital cognitive assessment used to evaluate and monitor conditions such as mild cognitive impairment and Alzheimer’s disease
- ■
The platform has facilitated more than 640,000 cognitive assessments and generated over 14,000 care plans, signaling growing adoption across care environments
BrainCheck just raised $13 Million to pursue a very specific mission: making cognitive care less fragmented and more systematic.
BrainCheck plans to expand what it calls its enterprise cognitive care infrastructure. That means tighter workflow integration inside clinics, long term patient monitoring, and deployment at population scale across both primary care and specialty settings. It is also investing in AI assisted clinical systems designed for risk bearing and value based care models, where providers are rewarded for outcomes rather than volume.
In plain terms, they want cognitive care to function less like a one off test and more like an ongoing program.
BrainCheck’s platform centers on BrainCheck Assess™, an FDA Class II cleared digital cognitive assessment. Clinicians in primary care, neurology, and psychiatry use it to evaluate and monitor conditions such as mild cognitive impairment and dementia, including Alzheimer’s disease. The tests are standardized and repeatable, available in English and Spanish, and customizable within the platform.
So far, the company reports more than 640,000 cognitive assessments completed and 14,000 care plans generated.
Leave a Reply